Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in Zucker diabetic fatty rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 2, 2014, Pages 423-431

  Kuriyama, Chiaki ^a   Xu, Jun Zhi ^b   Lee, Seunghun Paul ^b   Qi, Jenson ^b   Kimata, Hirotaka ^a   Kakimoto, Tetsuhiro ^a   Nakayama, Keiko ^a   Watanabe, Yoshinori ^a   Taniuchi, Nobuhiko ^a   Hikida, Kumiko ^a   Matsushita, Yasuaki ^a   Arakawa, Kenji ^a   Saito, Akira ^a   Ueta, Kiichiro ^a   Shiotani, Masaharu ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 5; HEMOGLOBIN A1C; INSULIN; RECOMBINANT PROTEIN; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; THIOPHENE DERIVATIVE;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELL FUNCTION; CELL STRUCTURE; DIABETES MELLITUS; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG SELECTIVITY; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLUCOTOXICITY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN BLOOD LEVEL; KIDNEY TUBULE ABSORPTION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN FUNCTION; RAT; RENAL GLUCOSE REABSORPTION; TREATMENT DURATION; URINARY EXCRETION; ZUCKER DIABETIC FATTY RAT; ANIMAL; DOG; EXPERIMENTAL DIABETES MELLITUS; HUMAN; KIDNEY; METABOLISM; PANCREAS ISLET; PATHOLOGY; ZUCKER RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DOGS; GLUCOSE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; KIDNEY; MICE; RATS; RATS, ZUCKER; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84908134817     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.217992     Document Type: Article

References (18)

1. Abdul-Ghani MA, DeFronzo RA, and Norton L (2013) Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 62:3324-3328.
2. Abdul-Ghani MA, Norton L, and Defronzo RA (2011) Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 32:515-531.
3. Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, and Cunard R, et al. (2012) Na (+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187-196.
4. Jones HB, Nugent D, and Jenkins R (2010) Variation in characteristics of islets of Langerhans in insulin-resistant, diabetic and non-diabetic-rat strains. Int J Exp Pathol 91:288-301.
5. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, and Zinman B, et al.; ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443.
6. Kakimoto T, Kimata H, Iwasaki S, Fukunari A, and Utsumi H (2013) Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4. J Endocrinol 216:13-20.
7. Kanai Y, Lee WS, You G, Brown D, and Hediger MA (1994) The human kidney low affinity Na1/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397-404.
8. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, and Pfister M (2009) Dapagliflozin, a novel SGLT2 inhibitor, induces dosedependent glucosuria in healthy subjects. Clin Pharmacol Ther 85:520-526.
9. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, and Conway B, et al. (2012) Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE 7:e30555.
10. Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T, Yamamoto Y, Ueta K, Kimata H, and Nakayama K, et al. (2010) Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 53:6355-6360.
11. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, and Anai M, et al. (1999) T-1095, an inhibitor of renal Na+ -glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48:1794-1800.
12. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, and Vallon V (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306:F188-F193.
13. Rossetti L, Giaccari A, and DeFronzo RA (1990) Glucose toxicity. Diabetes Care 13:610-630.
14. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, and Kemper M, et al. (2003) Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14:2873-2882.
15. Torres TP, Catlin RL, Chan R, Fujimoto Y, Sasaki N, Printz RL, Newgard CB, and Shiota M (2009) Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in zucker diabetic fatty rats. Diabetes 58:78-86.
16. Ueta K, O'Brien TP, McCoy GA, Kim K, Healey EC, Farmer TD, Donahue EP, Condren AB, Printz RL, and Shiota M (2014) Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity. Am J Physiol Endocrinol Metab 306:E1225-E1238.
17. Wright EM, Hirayama BA, and Loo DF (2007) Active sugar transport in health and disease. J Intern Med 261:32-43.
18. Yki-Järvinen H (1992) Glucose toxicity. Endocr Rev 13:415-431.